Treatment outcomes for various cancer indications certainly benefit from both early detection and the selection of the most appropriate targeted therapeutics, which are often guided in their use by companion diagnostic tests. In this second part of our series on bladder cancer we review how the new evolving ecosystem of precision medicine is playing a significant role in the research and development of new treatments for this condition. Read More
The rheumatoid arthritis (RA) market has come a long way since Enbrel (etanercept, Amgen Inc.) was first approved to treat the disease in 1998. Nearly two decades later, there are now a handful of additional TNF-alpha inhibitors, including some long-acting varieties, and multiple other drugs working through different mechanisms of action that have been approved by the FDA to treat RA. In addition to the multitude of biologics, there's even an oral disease-modifying antirheumatic drug (DMARD), Xeljanz (tofacitinib, Pfizer Inc.) that works by inhibiting Janus kinase (JAK). Read More
